Skip to main content

Market Overview

AstraZeneca's COVID-19 Vaccine Potentially Triggers Response Against Brazil Variant: Reuters


Preliminary data from a study conducted at the University of Oxford suggests that AstraZeneca Plc’s (NASDAQ: AZN) COVID-19 vaccine is effective against the P1 or Brazilian variant, reports Reuters.

  • The data indicate that the vaccine will not need modification to protect against the variant.
  • The study did not disclose the vaccine’s exact efficacy against the variant, but full results should be possibly released by March.
  • Early results from a small study showed that the AstraZeneca vaccine was less effective against the South African variant, similar to P1.
  • Subsequently, South Africa paused the use of the vaccine in the country.
  • Reuters also reported that a small-sample lab study showed that Sinovac Biotech’s COVID-19 vaccine failed to generate a sufficient immune response.
  • According to a recent study, one dose of either Pfizer Inc (NYSE: PFE)/BioNtech SE (NASDAQ: BNTX) or Oxford-AstraZeneca’s COVID-19 vaccine is more than 80% effective in reducing infections and severe illness among those aged over 80.
  • Price Action: AZN shares are trading 0.73% higher at $47.59 in market trading hours on the last check Friday.

Related Articles (AZN + PFE)

View Comments and Join the Discussion!

Posted-In: COVID-19 VaccineBiotech News Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at